The trial, which the health system announced Jan. 27, is completely virtual. It is recruiting COVID-19 patients across the New York City area who are experiencing only mild to moderate symptoms that do not require hospitalization.
Participants will be given either a placebo or 240 milligrams famotidine to take orally each day for a maximum of 14 days. They will receive training on how to track data from their homes using an iPad, Bluetooth-enabled scale, thermometer, fitness tracker, spirometer, thermometer and pulse oximeter.
“From assessment, to enrollment and daily data collection, we hope this study’s model will be an example for future clinical trials, and will provide high quality data as we assess candidate treatments, like famotidine, to curb this disease,” Tobias Janowitz, MD, PhD, the trial’s principal investigator said in a news release.
More articles on pharmacy:
Oklahoma trying to give back $2M hydroxychloroquine stockpile
Walgreens taps Starbucks exec as new CEO
Sanofi to manufacture 125M doses of Pfizer’s COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
